Business
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals – – Fourth quarter 2022 U.S. net product revenue estimated between $14.4 to $15.1 million, FY growth between 38% and 40% year over year – – New partnership with RFK Racing to increase brand awareness and drive accelerated growth – – Company presenting at J.P. Morgan 41st Annual Healthcare Conference – ANN ARBOR, Mich., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2022 financial results and highlighted key upcoming anticipated milestones which represent continued execution of the Company’s transformational plan. “Esperion stands committed to our strategic vision of driving accelerated growth and expansion of our bempedoic acid franchise, with the ultimate goal of reducing LDL cholesterol and improving cardiovascular outcomes, particularly in patients who are unable to tolerate or reach their goals with statins,” said Sheldon Koenig, Esperion’s president and chief executive officer. “With the robust CLEAR Outcomes data being presented and supporting regulatory submissions in the first half of 2023, we are poised to deliver significant value for shareholders in the coming months, as we look forward to potential label expansion and believe we will be entitled to receive partner milestone payments upon regulatory approvals. In line with our goal of increasing cardiovascular health awareness, we are also pleased to announce a new partnership with RFK Racing, which will provide ample opportunities for community engagement and education to their large and diverse consumer base. We look forward to building on our momentum in 2023 and beyond as we seek to maximize our opportunity with NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) and drive the franchise towards blockbuster status.” Preliminary Q4 2022 Financial Results Preliminary, unaudited fourth-quarter 2022 net U.S. product sales are expected to be between $14.4 to $15.1 million; FY growth between 38% and 40% year over year. As of December 31, 2022, cash and investment securities available-for-sale totaled approximately $167 million and there wer...